Evidence tracker Cardiac Red-cell transfusion

Restrictive versus liberal transfusion in cardiac surgery

Which transfusion threshold best balances oxygen delivery and transfusion exposure in cardiac surgery? Compare trial populations, ischemic outcomes, mortality, and the actual thresholds used—not anemia alone.

Indexed papers
10
matching, retractions excluded
Randomized trials
2
plus 0 meta-analyses
With AI summary
10
others show original abstract
Registered, not results
0
ongoing trials
Clinical assessment not completed. No bottom line, certainty grade, or curated effect sizes have been written for this topic. Below is a source-linked inventory of matching papers (up to 200 from our cache), not a systematic review. Read the original studies before drawing conclusions.

Published studies

Open in feed

Recent evidence appears first, ordered by publication date. Earlier evidence and papers without precise dates follow separately. Design categories are inferred from PubMed metadata, not evidence grades.

Showing 2 of 10 · RCT

Recent evidence · past year

  1. RCT Bone Jt OpenPublished 19 Oct 2026 RESULT Hip Study Group et al.
    RESULT-Hip. The impact of restrictive compared with liberal transfusion strategy on cardiac injury and death in patients undergoing surgery for hip fracture : protocol for a multicentre, randomized controlled trial of two blood transfusion strategies.
    AI summary of the abstract, unverified
    • Protocol for a multicentre randomized controlled trial in patients aged 60 or older with anaemia (haemoglobin ≤90 g/l) undergoing surgery for hip fracture.
    • Compares a liberal transfusion strategy (haemoglobin target 90 to 110 g/l) with a restrictive strategy (target 75 to 90 g/l) from randomization to discharge or 30 days.
    • No efficacy results are reported; the primary outcome is a composite of death or major adverse cardiac events, adjudicated by blinded experts, with quality of life assessed at 120 days.
    • The authors reduced the target sample size from 1,984 to 842 and added myocardial injury after non-cardiac surgery (MINS) to the primary outcome after recruitment fell short.
    Original abstract (PubMed)

    AIMS: Hip fracture is a global health issue. Complications are common, leading to reduced quality of life or death. These occur more frequently if anaemia is present. We hypothesize that correcting anaemia in the perioperative period may decrease major adverse cardiac events (MACE) and death after hip fracture. METHODS: This multicentre prospective randomized trial compares transfusion strategies after hip fracture in patients aged ≥ 60 years. We initially planned to randomize 1,984 participants with anaemia, defined as haemoglobin ≤ 90 g l-1, to one of two transfusion strategies: liberal transfusion (aim haemoglobin 90 g l-1 to 110 g l-1), or restrictive transfusion (aim 75 g l-1 to 90 g l-1). The intervention lasts from randomization to hospital discharge or 30 days post randomization, whichever is soonest. The primary outcome measure was a composite of death or MACE adjudicated by blinded clinical experts. Secondary outcomes included all-cause mortality and quality of life, evaluated at 120 days. Cost-effectiveness and health economic evaluation will also be reported. RESULTS: This trial was funded by the National Institute for Health and Care Research, HTA award (National Institute for Health and Care Research (NIHR) 130875) and registered at ISRCTN 28818784. Ethical approval was obtained to recruit patients in the UK. As recruitment fell short of the initial target, and following consultation with the funder, we refined our primary outcome to include myocardial injury after non-cardiac surgery (MINS), and reduced the required sample size to 842. CONCLUSION: Recruitment commenced on 10 June 2022. The first participant was recruited on 16 June 2022. We will engage clinicians and healthcare planners to implement the findings. We plan to recruit until 31 October 2026. Results will be disseminated to clinicians, policymakers, patients, and the public.

  2. RCT J Am Geriatr SocPublished 30 Jun 2026 Liang S et al.
    Perioperative Transfusion Trigger Score Versus Restrictive Transfusion in Older Non-Cardiac Surgery Patients: A Multicenter Randomized Controlled Trial.
    AI summary of the abstract, unverified
    • Multicenter randomized trial at two Chinese hospitals enrolled 253 patients aged 60 or older undergoing non-cardiac surgery, randomized 1:1.
    • Patients were assigned to POTTS-guided transfusion, a score built from adrenaline use, FiO2, temperature and angina history, or to control care following the 2012 AABB guideline.
    • Transfusion was required in 24.00% (30/125) of POTTS patients versus 35.94% (46/128) of controls (p = 0.038), with no significant difference in transfusion volume.
    • The authors concluded POTTS reduced the proportion transfused without increasing complications, though complication rates were 12.80% versus 8.59% (p = 0.279), not significantly different.
    Original abstract (PubMed)

    BACKGROUND: Restrictive transfusion (Hb < 7 g/dL) is recommended for most perioperative patients, but the optimal threshold for those with cardiovascular disease or Hb 7-10 g/dL remains uncertain. The Perioperative Transfusion Trigger Score (POTTS), which integrates adrenaline requirement, FiO2, temperature, and angina history, may standardize decisions and safely reduce transfusions in older non-cardiac surgery patients. METHODS: This multicenter RCT in two Chinese hospitals randomized patients ≥ 60 years undergoing non-cardiac surgery 1:1 to POTTS or control. POTTS = 6 plus points for adrenaline, FiO2 (to maintain SpO2 ≥ 95%), core temperature, and angina; transfusion when Hb < POTTS. Control followed 2012 AABB guideline (Hb < 7 always transfuse; > 10 not; 7-10 physician discretion). PRIMARY OUTCOME: proportion receiving allogeneic RBC transfusion during perioperative period (ITT population). RESULTS: 253 patients (mean age 72.3 years; 67.6% women) were randomized (May 2023-Sept 2025). Baseline Hb similar (median 9.60 vs. 9.50 g/dL). In ITT, transfusion required in 24.00% (30/125) of POTTS vs. 35.94% (46/128) of control (p = 0.038). Transfusion volume did not differ significantly (median 2.50 vs. 3.00 units, p = 0.520). Overall complication rates: 12.80% vs. 8.59% (p = 0.279); one death in control group (0.85%). No significant differences in specific complications. CONCLUSION: In patients ≥ 60 years undergoing non-cardiac surgery, POTTS-guided transfusion significantly reduced the proportion of patients transfused without increasing complications. TRIAL REGISTRATION: This study was registered at http://www.chictr.org.cn (#ChiCTR2300071739).

Earlier evidence / dates not confirmed

Includes older studies, year-only dates, and future-dated records. Inclusion does not imply landmark status.

  1. No matching papers in this section with the selected filters.

Ongoing registrations

From ClinicalTrials.gov

Registrations, not results. These registry entries describe ongoing studies, not their findings. They are not counted as published evidence above; check linked records for updates and associated publications.

No registered ongoing trials found.